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ABSTRACT  
6,17α-dimethyl-4,6-pregnadiene-3,20-dione (medrogestone, 2) is for a long time known steroid 
endowed with progestational activity. In order to study its crystallographic and NMR spectroscopic 
properties with the aim to fill the literature gap, we prepared medrogestone following a traditional 
procedure. A careful NMR study allowed the complete assignement of the 1H and 13C NMR signals 
not only of medrogestone but also of its synthetic intermediates. The structural and stereochemical 
characterizations of medrogestone togheter with its precursor 17α-methyl-3-ethoxy-pregna-3,5-
dien-20-one were described by means of X-ray analysis, allowing a deepened conformational 
investigation. 
 
Keywords: Progestin, progesterone, medrogestone, steroidal hormone, X-ray, NMR. 
 
 
 
1. INTRODUCTION 
Progesterone (4-pregnene-3,20-dione, 1) is the natural progestational agent. Progestational agents, 
natural or synthetic, are compounds that, like progesterone, are able to transform an endometrium 
primed by estrogens into a secretory status and are named progestins [1]. All known progestins 
belong to the class of steroids and are structurally related to pregnane or to androstane and estrane. 
The pregnane related progestins can differ from progesterone only for the presence of a 17α-
 hydroxy group, for the stereochemistry of C-10 or for the absence of C-19 [1,2]. The research 
devoted to the discovery of synthetic progestins is explained by the poor bioavailability on oral 
administration of progesterone, due to rapid metabolism in the liver that involves the reduction of 
20-keto group followed by the hydrogenation of 4,5-double bond and reduction of 3-keto group [3].  
Medrogestone (6,17α-dimethyl-4,6-pregnadiene-3,20-dione, Prothil®, 2) is a synthetic orally active 
progestin, known since sixties [4,5], used in the treatment of pathological deficiency of the natural 
hormone; in addition, its action on the enzymes involved in the estrogen biosynthesis and 
metabolism, in normal and cancerous breast cells, is still object of studies [6-9]. It is known, indeed, 
that a wide variety of progestinic analogs are potent inhibitors of enzymes involved in estrogen 
biosynthesis (sulfatase and 17β-hydroxysteroid dehydrogenase). These latter, at the same time, act 
by stimulating the sulfotransferase, the enzyme which converts estrogens into the biologically 
inactive sulfates. This double action leads to a significant reduction in estradiol biosynthesis which 
is aberrant in many breast tumors [10].  
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The structure of medrogestone 2 is closely related to that of progesterone 1, two methyl groups at 
position 6 and 17, respectively, and a double bond at position 6 being the only differences. The 
presence of the two methyl group is reported as mandatory for orally activity, probably due to the 
block of metabolic inactivation [11]. Indeed, the additional C-17 substituent could protect the 20-
keto group and the C-6 methyl group could slow down the A-ring reduction [3].   
Although medrogestone 2 is known for a long time, a careful NMR and crystallographic 
investigation is not yet reported. This lack of data prompted us to study, in addition to 
medrogestone, also its precursor 17α-methyl-3-ethoxy-pregna-3,5-dien-20-one (3) (Figure 1), either 
by NMR and X-ray analyses, and to describe the assignments of NMR spectra signals of the other 
intermediates involved in the synthetic route leading to 2. In particular, the solid state structure of 
the drug medrogestone allowed the complete stereochemical assignment of the stereocenters, 
together with the deeper description of its geometrical features with the aim to relate them to its 
precursor 3 and to natural progestin progesterone 1.  
Commercially available 3 is usually obtained by substitution of a 17α-acetoxy group, for example 
on 17α-acetoxy progesterone 4, with a methyl group, as described in Scheme 1 [12]. Starting from 
3 we introduced the 6-methyl group and the 6,7-double bond in order to obtain 2 and to isolate the 
synthetic intermediates. 
Since the main chemical physical properties of synthetic intermediates 3, 8, 9 and final 
medrogestone 2 are not reported in the literature, in this paper we wish to report their description, in 
order to provide a complete piece of information mainly useful from a preparative point of view and 
for relate them to the pharmacological properties endowed by this class of compounds. 
 
2. EXPERIMENTAL 
2.1 General 
All reagents and solvents were purchased from Sigma-Aldrich. 17α-methyl-3-ethoxy-pregna-3,5-
dien-20-one (3) was purchased from Xi’an Reyphon Pharmaceutical CO Ltd, China.  
TLC analyses were performed on silica gel 60 F254 precoated plates with a fluorescent indicator 
(Merck) with detection by a 5% phosphomolybdic acid solution in ethanol and heating at 110 °C. 
The DSC (Differential Scanning Calorimetry) were registered on a Perkin Elmer instrument (Mod. 
DSC7) at a heating rate of 30 °C/min from 50.0 °C to 280.0 °C.  
Infrared spectra were recorded on a Perkin Elmer instrument (Mod. Spectrum One FT-IR) equipped 
with ATR sampling device. 
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Mass spectra were recorded on an Agilent 6330 Ion Trap instruments (ESI positive) using the direct 
inlet probe technique; the samples of compounds 2, 8 and 9 were dissolved in a 0.1M formic acid 
solution in methanol/water mixture (1:1) at a final concentration of 0.002 mg/ml and injected at an 
infusion rate of 0.5 ml/hour. The sample of compound 3 was dissolved in methanol at a final 
concentration of 0.002 mg/ml and injected at an infusion rate of 0.5 ml/hour. 
HPLC system consisted of an Agilent 1100-series liquid chromatography, equipped with auto 
injector, DAD detector and a Chemostation software installed on a PC, for data collecting and 
processing. A Symmetry C 18 (Waters) column (250 x 4.6 mm, 5µm) was employed. Column 
temperature: 25 °C. Mobile phase: A (acetonitrile/water 6:4); B (acetonitrile/water 95:5). Elution 
gradient from 100% A (0-33 min) to 100% B (34-45). Detection UV: wavelength 245 nm. Flow 
rate: 1.0 mL/min. 
Optical rotation values were registered on a Perkin Elmer instrument (Mod 241) at 589 nm and 25 
°C. 
 
2.2 Chemistry 
2.2.1 3-ethoxy-17α-methyl-3,5-pregnadien-20-one (3). Chemical-physical properties: Rf 0.67 
(hexane/ethyl acetate 1:1). DSC endothermic peak at 130.00 °C. IR ν (cm-1) 2972-2813, 1700, 
1650, 1624, 1172. MS (m/z) 357.4 [M+1]+, 379.4 [M+Na]+. [α]D25 -117.2 (c 1, CH2Cl2). 
2.2.2 3-ethoxy-6-formyl-17α-methyl-3,5-pregnadien-20-one (9)  
Title compound 9 was prepared from 3 as reported in Ref [13]. 4.14 g, 77% (lit[13] 87.5%). Rf  0.53 
(hexane/ethyl acetate 1:1). DSC endothermic peak at 83.6 °C (crystallization from 
methanol/trimethylamine 99:1). MS (m/z) 385.4 [M+1], 407.4 [M+Na]+, 423.3 [M+K]+. IR ν (cm-1) 
2976-2751, 1701, 1648, 1606, 1578, 1159. [α]D25 -142.9 (c 1, CH2Cl2). 
2.2.3 17α-methyl-6-methylene-4-pregnen-3,20-dione (8) 
6-Methylene 8 was prepared from 9 according to Ref [13]. 3.3 g, 94 % (lit[13] 62.7%). Rf  0.44 
(toluene/ethyl acetate/triethylamine 70:30:1). DSC endothermic peak at 181.61 °C (crystallization 
from methanol). IR ν (cm-1) 2944-2834, 1840, 1695, 1668, 1658, 918. MS (m/z) 341.4 [M+1]+, 
363.4 [M+Na]+, 379.3 [M+K]+. [α]D25 +264.3 (c 1, CH2Cl2).  
2.2.4 6,17α-methyl-4,6-pregnadien-3,20-dione (medrogestone) (2) 
Pure 2 was prepared from 8 in 87% yield (2.6 g) as reported [13] (lit[13] 70.8%). Rf  0.42 
(toluene/ethyl acetate/triethylamine 70:30:1). DSC endothermic peak at 154.8 °C (crystallization 
from 2-propanol). IR ν (cm-1) 2970-2858, 1691, 1663, 1631, 1593. MS (m/z) 341.4 [M+1]+, 363.4 
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[M+Na]+, 379.3 [M+K]+. [α]D25 +79.1 (c 1, CHCl3, lit[14] +79). El. Analysis (C23H32O2): Calc. C 
81.13, H 9.47, O 9.40. Found C 81.17, H 9.46, O 9.49.  
 
2.3 NMR spectroscopy  
NMR spectra were recorded on a Bruker AVANCE 500 spectrometer equipped with a 5mm 
broadband inverse NMR probe with field z-gradient operating at 500.13 and 125.76 MHz for 1H 
and 13C, respectively. NMR spectra were recorded at 298 K for compounds 2, 8, 9 in CDCl3 
(isotopic enrichment 99.95%), for compound 3 in pyridine-d5 (isotopic enrichment 99.95%) 
solution and the chemical shifts were reported on a δ (ppm) scale. The central peak of CDCl3 
signals (7.24 ppm for 1H and 77.7 ppm for 13C) and of pyridine-d5 signals (7.22 ppm, higher field 
signal, for 1H and 123.9 ppm, higher field signal, for 13C spectra respectively) were used as an 
internal reference standard. The data were collected and processed by XWIN-NMR software 
(Bruker) running on a PC with Microsoft Windows 7. The samples (10 mg), were dissolved in 
appropriate solvent (0.7 mL) in a 5 mm NMR tube. Acquisition parameters for 1D were as follows: 
1H spectral width of 5000 Hz and 32K data points providing a digital resolution of ca. 0.305 Hz per 
point, relaxation delay 2 s; 13C spectral width of 29,412 Hz and 64 K data points providing a digital 
resolution of ca. 0.898 Hz per point, relaxation delay 2.5 s. The experimental error in the measured 
1H-1H coupling constants was ±0.5 Hz.  
For two-dimensional experiments, standard Bruker microprograms using gradient selection (gs) 
were applied. Gs-COSY-45 and phase sensitive gs-NOESY experiments were acquired with 512 t1 
increments; 2048 t2 points; spectral width 10.0 ppm. The gs-NOESY experiments were performed 
with a mixing time of 0.800 s on samples degassed under a flush of argon in a screw-cap sample 
tube. There were not significant differences in the results obtained at different mixing times (0.5–
2.0 s).The acquisition data for gs-HSQC and gs-HMBC experiments were acquired with 512 t1 
increments; 2048 t2 points; spectral width 10.0 ppm for 1H , 180 ppm for 13C, gs-HSQC and 160-
260 ppm for gs-HMBC experiments). Delay values were optimized for 1JC,H 200.0 Hz or 140 Hz, 
nJC,H 3.0 Hz. Zero filling in F1 to 1 K, pi/2 shifted sine-bell squared (for gs-HSQC) or sinebell (for 
gs-HMBC) apodization functions were used for processing.  
For overlapped signals of hydrogen atoms the 1D HOHAHA technique [15] was used to obtain the 
chemical shifts and coupling constants. 
 
2.4 X-ray Crystallography 
Crystals of 2 and 3 were obtained as colorless prisms from water/ethanol 1:1 and water/methanol 
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1:1 solutions at room temperature, respectively. Intensity data were collected at room temperature 
on a Bruker Apex II CCD diffractometer, using graphite-monochromatized Mo-Kα radiation (λ = 
0.71073 Å). Intensity data were corrected for Lorentz-polarization effects and for absorption 
(SADABS [16]). The structures were solved by direct methods (SIR97 [17]) and completed by 
iterative cycles of full-matrix least squares refinement on Fo2 and ∆F synthesis using the SHELXL-
97 [18] program (WinGX suite) [19]. The positions of hydrogen atoms were introduced at calculated 
positions, in their described geometries and allowed to ride on the attached carbon atom with fixed 
isotropic thermal parameters (1.2Ueq of the parent carbon atom). A summary of crystal data and 
refinement is reported in Table 1. 
These data can be obtained via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge 
Crystallographic Data Centre, 12, Union Road, Cambridge CB21EZ, UK; fax: ++44 1223 336 033; 
or deposit@ccdc.cam.ac.uk). CCDC-1058837 (2) and 1058836 (3) numbers contain the 
supplementary crystallographic data for this paper. 
 
 
 
 
3. RESULTS AND DISCUSSION 
3.1 Chemistry 
Six stereogenic centers are present in the molecule of medrogestone 2, namely the C-8, C-9, C-10, 
C-13, C-14 and C-17, with configuration reported in Figure 1. The stereochemistry of  the first five 
centers is determined considering the starting material of the synthesis, the 17α-acetoxy 
progesterone 4, that is submitted to a 6 and a 17α-methylation. The 6-methyl group is usually 
introduced on a 3-ethylenol ether of a 3,5-diene derivative by means of a Vilsmeier reaction (DMF, 
POCl3) [20] that leads to a 6-formyl derivative. Reduction of carbonyl function, followed by 
dehydration by acidic treatment, affords the 6-methylene intermediate that is isomerized to the 
desired 6-methyl-4,6-diene. An alternative method [21] provides the reaction of a 5α,6α-epoxide 
with bromomethyl magnesium in order to obtain the 5α-hydroxy, 6β-methyl derivative that by 
treatment with sulfuric acid affords the 3-keto-∆4-derivative; dehydrogenation by means of 
chloranil furnishes the 6,7-double bond. According to a 1965 United States patent [22], the suitable 
intermediate is, in this case, a 5α,6α-diol. Oxidation of 6-hydroxy group affords the carbonyl 
function that, by treatment with methyl magnesium bromide and dehydration is transformed into the 
final 6-methyl-4,6-diene.  
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The 17α-methyl group is introduced by the known reductive alkylation [12] of the suitable acetoxy 
derivative 5. Lithium in liquid ammonia causes the formation of enolate 6 that by treatment with 
methyl iodide furnishes the desired 17α-methyl derivative 7. In the course of this alkylation, the 
sixth stereocenter (C-17) is introduced, the methyl group attack occurring from the α-side of the 
molecule, that is the same side where the leaving group is bonded. (Scheme 1) 
We decided to prepare medrogestone 2, necessary for crystallographic and spectroscopic studies, 
starting from the commercially available 17α-methyl-3-ethoxy-pregna-3,5-dien-20-one 3. 
According to the above cited 1964 method [20] and following the recent revisitation and application 
of this synthetic route to the 17α-methyl derivative, proposed in a 2006 Solvay patent [13], the 6-
methylene intermediate 8 was prepared by introduction of a 6-formyl group (compound 9) followed 
by reduction to the corresponding alcohol. Desired medrogestone 2 was obtained after dehydration 
and isomerization of obtained 6-methylene 8 (Scheme 2). The isomerization of 6-exo double bond 
to the 6,7 one can be realized by acidic treatment [23], or according to a 1965 method by reaction 
with palladium on charcoal, sodium acetate and cyclohexene in ethanol [24]. According to the 
recent modification of this procedure [13], final medrogestone 2 was obtained in 87% yields from 8 
and 63% overall yields from 3.   
3.2 NMR spectroscopy 
The NMR study was carried out either on medrogestone 2, on its commercially available precursor 
3 and on 8 and 9 intermediates (Scheme 2). Compounds 2, 8, and 9 were dissolved in CDCl3, while 
compound 3 was dissolved in d5-pyridine in order to avoid the fast degradation of the enol ether 
moiety, observed in chloroform. Unambiguous assignments of protons and carbons of compounds 
(Tables 2 and 3) were recognized by 1D NMR spectra, as well as 2D NMR homocorrelation 
(COSY, TOCSY and NOESY) and heterocorrelation (HSQC and HMBC) spectra were employed 
for complete structural assignments. For overlapped signals of hydrogen atoms in the final product 
2, the 1D HOHAHA [15] technique was used to obtain the chemical shifts and coupling constants. 
Most of the proton assignments were accomplished using general knowledge of chemical shift 
dispersion with the aid of the proton-proton coupling pattern (1H NMR spectra), the gs-COSY and 
gs-NOESY experiments. In ambiguous cases, the gs-HSQC and gs-HMBC spectra were used as a 
final and unequivocal tool to make specific assignment.  
In particular, in medrogestone 2 1H NMR chemical shifts of H-2α and H-2β (2.59 and 2.45 ppm) 
and H-16β (2.70 ppm) protons can be assigned to the influence of the anisotropy of the neighboring 
carbonyl group. Starting from the characteristic resonances of this three protons and the two olefinic 
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protons H-4 (5.87 ppm) and H-7 (5.98 ppm) it was possible to assign the resonances of all the other 
protons. 
NOE experiments were performed to confirm the configuration of the 17-CH3. The following 
significant enhancements were observed when methyl protons at 1.15 ppm were irradiated (Figure 
2). The NOE correlations of 17-CH3 (1.15 ppm) with H-15α, H-16α and H-14α indicated that all 
these protons were on the same face of the ring system. On the other hand, the NOE correlations of 
CH3-21 (2.15 ppm) with CH3-18, H-16β and H-12β showed that these protons were on the opposite 
face of the ring system demonstrating unequivocally that the 17-CH3 was in α position.  
When the CH3-18 (0.77 ppm) was irradiated, NOE enhancement was observed on H-8β, H-11β, H-
15β, H-16β, and CH3-21; when the CH3 in C-6 (1.85 ppm) was irradiated, NOE enhancement was 
observed on H-4 and H-7. Finally NOE were observed on H-2β, H-8β and on proton at 2.02 ppm, 
assigned to the H-1β, when the CH3-19 (1.10 ppm) was irradiated. 
The assignments of carbon atoms of CH, CH2 and CH3 groups were confirmed by the gs-HSQC 
experiment. The quaternary carbon atoms were assigned unambiguously using the information 
obtained from 1H/13C gsHMBC experiment.  
1H NMR and 13C NMR spectra of compounds 3, 8 and 9 showed similar chemical shifts and 
coupling constants to those of 2 except for C/H-6, C/H-7 and C/H-8, due to different double bond 
position, putting in evidence that these compounds closely resemble compound 2. In particular, the 
same relative configuration of 17-CH3 of the latter was determined also in precursor 3, based on its 
NOE correlations. Indeed, when the signal at 1.03 ppm (17-CH3) was irradiated NOE was observed 
on H-15α, H-16α and H-14α showing that these protons were on the same side of the D ring. 
 
3.3 X-Ray analysis  
We started the X-ray analysis examining the molecular structure of the commercially available 
precursor 3 (see Scheme 2) in order to assess the maintenance of the proper stereochemistry at C17 
during the synthetic route leading to 2. 
Compound 3 crystallized with two independent molecules in the asymmetric unit, that are shown in 
Figure 3 as a ORTEP [25] drawing, while the solid state conformation of medrogestone (2) is 
shown in Figure 4. 
The crystallographic data allowed the complete stereochemical assignment of all the stereogenic 
carbons for both compounds and their absolute configuration was assigned according to the known 
S configurations of C9, C10 and C13, which were unaffected in the reaction pathway. Consequently, 
it was possible to unambiguously establish for both compounds the stereochemistry S at C17. 
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Their overall molecular structure is characterized by the common tetracyclic skeleton formed by 
three condensed hexatomic rings fused with a pentacyclic ring, all in trans configuration. 
The two entities of 3 have a very similar geometry, except for a slightly different orientation of the 
lateral chain linked to C3 (see Figure 5), as indicated by the torsion angles τ1 C16-C17-C20-O2 of 
6(1)[-13(1)]°, τ2 C4-C3-O1-C23 of 5(1)[2(1)]° and of τ3 C2-C3-O1-C23 -174(1)[-179(1)]°. The 
values in the square brackets refer to the “b” labeled molecules.  
The two molecules of the precursor and the final product have a similar rings conformation and the 
main deviations are related to the φ angles values of the six-membered rings, indicating their 
different puckering (Table 4) [26]. The A and B rings exhibit a “twisted envelope” conformation, 
but in 3 the ring A is less distorted with respect to 2. In the precursor, atom C10 of ring A has the 
higher distance from the mean plane C1/C2/C3/C4/C5, being 0.618(1)[0.580(1)] Å, while in 2, the 
out-of-plane atom is C1 by 0.593(1) Å. In ring B, the distances of C8 and C9 calculated from the 
best mean plane of the remaining ring atoms are 0.324[0.318] and 0.423[0.426] Å in 3 and they are 
0.251(1) and 0.787(1) Å for 2, respectively. The ring C is in chair conformation, with atoms C9 and 
C13 out of the mean plane of C8/C14/C12/C11, with distances for C9 of 0.593(2)[0.720(2) Å] and 
for C13 of -0.713(3)[-0.585(2)] Å in 3, while they are 0.705(1) and -0.664(1) Å in 2. The 
pentatomic cycle D has a similar distorted envelope conformation in both compounds, with the 
atom C13 out of mean plane C14/C15/C16/C17 by 0.671(3)[-0.666(3)] Å in 3 and by 0.665(1) Å in 
2. The different rings conformation between the two molecules is also put in evidence in Table 5 
where at least one significant torsion angle for every ring is reported. In addition, their structural 
differences could be best showed in the superimposition reported in Figure 6. 
In conclusion, this solid state investigation allowed the complete stereochemical assignment of the 
asymmetric carbons together with the deeper description of its geometrical features with the aim to 
relate them to the pharmacological properties endowed by this class of compounds. Referring to the 
previous structure-activity-relationship (SAR) [27,28], we can confirm for medrogestone the quite 
rigidity of the molecular tetracycle, in particular of rings B, C and D. Though the presence of a 
double bond in ring B, medrogestone mantains a similar value of the distance between the carbonyl 
oxygens O1…O2 with respect to progesterone, being 11.7(1) Å. As the orientation of the acetyl side 
chain is able to influence the progestinic activity, we found in the solid state of 2 a value of τ1 of -
9(1)°, that is in agreement with that determined in other compounds [29]. In this respect, NOESY 
spectra demonstrated that the chain can assume different orientations, leading to a populated class 
of conformers.  
The availability of X-ray and NMR data of medrogestone could be a useful starting point for the 
study of similar molecules. Since the synthetic intermediates could be utilized also for the 
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preparation of other steroidal compounds, the reported spectroscopic and chemical physical data 
have a value not limited only to the present work. Besides, this complete characterization is relevant 
as could help in defining the bioactive conformation of this drug.  
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Figure 1. Structures of progesterone 1 and related compounds 2-4.   
 
Figure 2. Key NOE correlations for compound 2. 
 
Figure 3. ORTEP [25] drawing of 3. For sake of clarity, only molecule “a” of the two independent 
molecules present in the asymmetric unit shows the labeling scheme which is followed also by 
molecule “b”. Thermal ellipsoids are at 40% probability. 
 
Figure 4. ORTEP [25] of 2 showing the atom labeling scheme. Thermal ellipsoids are at 40% 
probability. 
 
Figure 5. Superimposition of the two independent molecules of 3 obtained through the best rms fit 
of the tetracyclic atoms: the “a” labeled ones is reported in green. 
 
Figure 6. Overlay between 2 (red) and 3 (“a” molecule in green) obtained through the best rms fit of 
C1 and C16 atoms. 
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Table 1. Summary of crystal data and refinement of 3 and 2. 
Identification 3 2 
Empirical formula C24 H36 O2 C23 H32 O2 
Formula weight 356.53 340.49 
Temperature [K] 294(2) 294(2) 
λ MoKα (Å) 0.71073 0.71073 
Crystal system Monoclinic Monoclinic 
Space group P 21 P 21 
Unit cell dim.(Å, °) a= 16.401(3) a = 10.386(2) 
 b= 7.500(1) b = 6.527(1) 
 c = 18.185(4) c = 14.507(3) 
Crystal size (mm) 0.3x0.20x0.15 0.25x0.20x0.15 
Volume (Å3) 2106(1) 979(3) 
Z 4 2 
Density (calc. Mg/m3) 1.125 1.155 
Refinement method Full matrix least square on F2 
F(000) 784 372 
θ range data coll. (°) 1.19 to 27.18 1.41 to 32.35 
Index ranges 
-21≤h≤21 -15≤h≤14 
 
-9≤k≤9 -9≤k≤9 
 
-23≤l≤23 -21≤l≤21 
Refl. coll. (Indep.) 5492/9328 3897/6320 
Data/restraints/param. 9379/ 1 / 469 6320 / 1 / 226 
Goodness-of-fit on F
2
 
1.023 0.906 
Final R ind. [I>2σ(I)] R1 = 0.059 R1 = 0.048 
 wR2 = 0.136 wR2 = 0.1312 
Largest diff. peak and hole(e/ Å3) 0.197;-0.250 0.21;-0.168 
 
 
  
Table 2. 
1
H NMR chemical shifts (ppm)
a
 and coupling constants (Hz)
b
 of compounds 2, 3, 8, and 9  
1
H 2 (CDCl3) 3 (Py-d5) 8 (CDCl3) 9 (CDCl3) 
1α (ax) 1.73  (ddd) 
-13.7 (1β), 13.7 (2β), 5.4 (2α) 
1.33 (ddd) 
-13.2 (1β), 13.2 (2β), 5.4 (2α) 
1.77 (ddd) 
-13.3(1β), 13.3 (2β), 5.4 (2α) 
1.46 
-13.2 (1β), 13.2 (2β), 5.4 (2α) 
1β (eq) 2.03 (ddd) 
-13.7 (1α), 5.4 (2β) , 2.2 (2α) 
1.79 
nd 
2.08 (ddd) 
-13.3 (1α), 5.2 (2β) , 2.6 (2α) 
1.99 (ddd) 
-13.2 (1α), 5.7 (2β) , 1.6 (2α) 
2α (eq) 2.45 (ddd) 
-17.9 (2β), 5.2 (1α), 2.2 (1β) 
2.25 (ddd) 
-17.8 (2β), 5.4 (1α), 1.8 (1β) 
2.40 (ddd) 
-17.3 (2β), 5.4 (1α), 2.6 (1β) 
2.25 (ddd) 
-18.1 (2β), 5.4 (1α), 1.6 (1β) 
2β (ax) 2.59 (ddd) 
-17.9 (2α), 13.7 (1α), 5.4 (1β) 
2.41 (ddd) 
-17.8 (2α), 13.2 (1α), 5.4 (1β) 
2.47  
nd 
2.41(ddd) 
-18.1 (2α), 13.2 (1α), 5.7 (1β) 
4 5.87 (bs) 5.33 (s) 5.93 (s) 6.31 (s) 
5 - - - - 
6 - 5.36 (bs) - - 
6-CH3 1.85 (s) - - - 
7α (ax) 
5.98 (bs) 
1.68 
nd 
1.90 
nd 
1.73 
nd 
  
7β (eq) 2.15 
nd 
2.48 
nd 
2.56 (dd) 
-17.9 (7α) 5.5 (8β) 
8β (ax) 2.22 (dd) 
10.6 (9 α), 12.4 (14α) 
1.66 
nd 
1.70 
nd 
1.63 
nd 
9α (ax) 1.22 (ddd) 
13.4 (11β), 10.6 (8β), 3.4 (11α) 
0.98 
nd 
1.14 
nd 
1.03 (ddd) 
11.6 (11β), 11.6 (8β), 4.6 (11α) 
11α (eq) 1.65 (dddd)* 
-13.2 (11β), 4.2 (12α), 2.4 (12β), 
3.4 (9α) 
1.61 
nd 
1.71 
nd 
1.68 
nd 
11β (ax) 1.44 (dddd) 
13.4 (9α), -13.2 (11α), 12.5 (12α), 
3.6 (12β) 
1.39 
nd 
1.47 (dddd) 
13.0 (9α), -13.4 (11α), 12.5 (12α), 
4.0 (12β) 
1.49 
nd 
12α (ax) 1.62 (ddd)* 
-12.5 (12β), 12.5 (11β), 4.2 (11α) 
1.49 
nd 
1.66 
nd 
1.63 
nd 
12β (eq) 1.91 (ddd)* 
 -12.5 (12α), 3.6 (11β), 2.4 (11α) 
1.80 
nd 
1.91 
nd 
  1.90 
nd 
14α (ax)
 
 1.66 (ddd)* 
12.4 (8β), 11.4 (15β), 7.6 (15α) 
1.54 
nd 
1.53 (ddd) 
12.4 (8β), 11.2 (15β), 7.6 (15α) 
1.53 
nd 
  
15α (eq) 1.39 (dddd)* 
-12.1, (15β), 9.5 (16α), 7.6 (14α),  
2.9 (16β) 
1.15 
nd 
1.29 
nd 
1.28 
nd 
15β (ax) 1.89 (dddd)* 
-12.1, (15α), 11.4 (14α), 11.3 
(16β), 6.4 (16α) 
1.64 
nd 
1.76 (dddd) 
-12.1, (15α), 11.2 (14α), 11.9 
(16β), 5.9 (16α) 
1.87 
nd 
16α (ax) 1.33 (ddd)* 
-14.4 (16β), 9.5 (15α), 6.4 (15β) 
1.24 
nd 
1.30 
nd 
1.33 
nd 
16β (eq) 2.70 (ddd) 
-14.4 (16α), 11.3 (15β), 2.9 (15α) 
2.83 (ddd) 
-13.9 (16α), 11.3 (15β), 3.0 (15α) 
2.66 (ddd) 
-13.7 (16α), 11.9 (15β), 3.1 (15α) 
2.65 (ddd) 
-13.7 (16α), 11.5 (15β), 3.1 (15α) 
17  - -   
18-CH3  0.76 (s) 0.73 (s) 0.72 (s) 0.72 (s) 
19-CH3  1.10 (s) 1.10 (s) 1.11 (s) 1.10 (s) 
20 - - - - 
21-CH3 2.15 (s) 2.14 (s) 2.14 (s) 2.14 (s) 
17α-CH3 1.15 (s) 1.03 (s) 1.16 (s) 1.15 (s) 
CH2CH3 - 3.76 (q) 
7.0 (CH3) 
- 3.92 (q) 
7.0 (CH3) 
CH2CH3 - 1.25 (t) - 1.38 (t) 
  
7.0 (CH2) 7.0 (CH2) 
C=CHH - - 5.07 (dd) 
-2.1 (CH), 2.1 (7) 
- 
C=CHH - - 4.95 (dd) 
-2.1 (CH), 2.1 (7) 
- 
CHO - - - 10.26 (s) 
 
nd = J(H,H) were not determined due to the overlapping;  ax = axial; eq = equatorial;  m = multiplet. 
a 
assignments from 
1
H-
1
H COSY, HSQC, HMBC and HOHAHA data. 
b 
coupling constants were obtained by direct inspection of the spectra, except those marked with an asterisk, which were obtained by HOH 
experiments. Experimental error in the measured 
1
H-
1
H coupling constants was ± 0.5 Hz.  
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Table 3. 13C NMR data of compounds 2, 3, 8, and 9  
13C 2 (CDCl3) 3 (Py-d5) 8 (CDCl3) 9 (CDCl3) 
1 34.1 35.7 35.2 32.9 
2 33.6 26.3 33.8 25.3 
3 200.0 154.9 200.0 161.8 
4 121.1 100.2 121.7 92.3 
5 164.3 141.5 168.9 159.4 
6 131.2 118.5 145.9 125.5 
6-CH3 19.9 - - - 
7 138.5 32.7 40.0 29.4 
8 37.3 32.5 35.8 30.9 
9 50.6 48.5 52.2 47.2 
10 36.1 35.7 39.0 28.0 
11 20.4 21.6 20.8 20.9 
12 32.9 34.4 32.7 32.7 
13 45.2 45.0 44.4 44.4 
14 48.4  52.2  50.9 51.6 
15 23.3 24.5 23.7 23.8 
16 31.2 31.9 31.2 31.3 
17  61.3 62.1 61.4 61.5 
18-CH3  15.8 16.3 15.8 15.9 
19-CH3  16.4 18.9 17.1 18.9 
20 212.1 211.7 212.1 212.5 
21-CH3 27.9 28.2 27.9 27.9 
17α-CH3 21.5 22.0 21.5 21.6 
CH2CH3 - 62.7 - 63.0 
CH2CH3 - 15.2 - 14.5 
C=CHH - - 114.2 - 
CHO - - - 190.4 
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Table 4. Summary of the puckering [26] parameters. 
Ring 3 b 2 
 QT (Å) ϑ (°) ϕ (°) QT (Å) ϑ (°) ϕ (°) 
A:C1/C2/C3/C4/C5/C10 0.447(3)[0.452(3)] 52.41(4)[49.4(3)] -150.0(5)[-147.3(4)] 0.436(2) 50.4(2) -105.7(3) 
B:C5/C6/C7/C8/C9/C10/ 0.489(3)[0.486(2)] 130.6(4)[131.4(4)] -34.6(5)[-35(5)] 0.485(2) 130.6(2) -84.3(2) 
C:C8/C9/C11/C12/C13/C14 0.555(3)[0.554(2)] 7.83(3)[8.9(2)] 176.5(2)[-116.7(1)] 0.588(2) 5.1(1) -55(2) 
D:C13/C14/C15/C16/C17 / / -154.8(6)[158.3(2)] / / -153.1(3) 
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Table 5. Selected torsion angles of the tetracycle. 
Torsion angle (°) Compound 
 3 a 3 b 2 
C10–C1–C2–C3 -44 -45 -54 
C5–C6–C7–C8 14 14 1 
C9–C11–C12–C13 -55 -54 85 
C14–C13–C17–C20 159 159 159 
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Crystallographic and spectroscopic study on a known orally active progestin 
P.Ferraboschi, P. Ciuffreda, S. Ciceri, P. Grisenti, C. Castellano, F. Meneghetti. Steroids 
 
 
 
Conformational and 
stereochemical 
characterization of 6,17α-
dimethyl pregnan-4,6-dien-
3-one (medrogestone, red) 
and its precursor 17α-
methyl-3-ethoxy-pregna-3,5-
dien-20-one (green) by 
means of X-ray and NMR 
analysis 
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Few chemical physical and spectral data of medrogestone are described in literature.  
NMR and X-ray data  are a useful starting point for the study of similar compounds. 
The synthetic intermediates and the final product chemical physical data are reported. 
 
